Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 2Peritoneal Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 26Nivolumab 18enfortumab vedotin 7avelumab 6atezolizumab 6Ipilimumab 6Magnetic Resonance Spectroscopy 5fludarabine 4cabozantinib 4Gemcitabine 4Cyclophosphamide 4Carboplatin 4Specimen Handling 3Interleukin-2 3Docetaxel 3130-nm albumin-bound paclitaxel 3aldesleukin 2Platinum 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Immunoglobulin G 2Fluorodeoxyglucose F18 2FAPI-46 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2vinflunine 1veliparib 1valrubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Transitional Cell × soluble LAG-3 protein, human × Clear all
NCT03252938 2026-02-19

INSIGHT

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 1 Active not recruiting
83 enrolled
GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡